AU2002214835A1 - Treatment of osteoporosis - Google Patents

Treatment of osteoporosis

Info

Publication number
AU2002214835A1
AU2002214835A1 AU2002214835A AU1483502A AU2002214835A1 AU 2002214835 A1 AU2002214835 A1 AU 2002214835A1 AU 2002214835 A AU2002214835 A AU 2002214835A AU 1483502 A AU1483502 A AU 1483502A AU 2002214835 A1 AU2002214835 A1 AU 2002214835A1
Authority
AU
Australia
Prior art keywords
metal ion
mammal
xylan
polysulfate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214835A
Other languages
English (en)
Inventor
David Cullis-Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arthropharm Pty Ltd
Original Assignee
Arthropharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthropharm Pty Ltd filed Critical Arthropharm Pty Ltd
Publication of AU2002214835A1 publication Critical patent/AU2002214835A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002214835A 2000-11-21 2001-11-19 Treatment of osteoporosis Abandoned AU2002214835A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/716,818 US6593310B1 (en) 2000-11-21 2000-11-21 Treatment of osteoporosis
US09716818 2000-11-21
PCT/AU2001/001492 WO2002041901A1 (fr) 2000-11-21 2001-11-19 Traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
AU2002214835A1 true AU2002214835A1 (en) 2002-06-03

Family

ID=24879564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214835A Abandoned AU2002214835A1 (en) 2000-11-21 2001-11-19 Treatment of osteoporosis

Country Status (9)

Country Link
US (1) US6593310B1 (fr)
EP (1) EP1335733B1 (fr)
JP (1) JP2004513185A (fr)
CN (1) CN1476328A (fr)
AT (1) ATE357923T1 (fr)
AU (1) AU2002214835A1 (fr)
CA (1) CA2426929A1 (fr)
DE (1) DE60127575T2 (fr)
WO (1) WO2002041901A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
WO2004014886A1 (fr) * 2002-08-07 2004-02-19 University Of Mississippi Agents anti-giardiase et leur utilisation
US20060068036A1 (en) * 2002-12-31 2006-03-30 National Yang-Ming University Extract of Dioscorea sp. and the medical uses thereof
US20040126447A1 (en) * 2002-12-31 2004-07-01 Rong-Tsun Wu Extract of Dioscorea sp. and the medical uses thereof
US8668908B2 (en) * 2002-12-31 2014-03-11 National Yang-Ming University Method for alleviating chemotherapy side effects using extract of Dioscorea sp
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
MXPA05014091A (es) * 2005-12-20 2007-06-20 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden derivados de esteroides sinteticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevencion y tratamiento de la osteoporosis y el control de los sintomas de la menopaus
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
US20110129544A1 (en) * 2007-02-22 2011-06-02 Tatsuya Miyazaki Bone/Cartilage Formation-Stimulation Agent
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
AU2008100730B4 (en) * 2008-07-04 2008-10-02 Parnell Technologies Pty Ltd Sulfated polysaccharide compound for clinical use and the preparation thereof
EA019794B1 (ru) * 2008-07-09 2014-06-30 Мелальюка, Инк. Комплекс для доставки млекопитающему минерала
TWI520740B (zh) 2011-02-02 2016-02-11 模範健康科技私人企業有限公司 利用多硫酸化多醣之骨髓水腫（水腫）的治療
CN102988679A (zh) * 2012-10-16 2013-03-27 杨晓兵 一种益肾健脾防治骨质疏松的药物组合物
JP6225321B1 (ja) 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
SG11202001824RA (en) 2016-08-31 2020-04-29 Oji Holdings Corp Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6281659B1 (ja) * 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
CA3065747A1 (fr) 2017-05-31 2018-12-06 Oji Holdings Corporation Composition hydratante comprenant un polysulfate de pentosanne
SG11202000938YA (en) 2017-08-04 2020-02-27 Paradigm Biopharmaceuticals Ltd Treatment of bone marrow pathologies with polysulfated polysaccharides
MX2020002726A (es) 2017-09-12 2020-07-20 Oji Holdings Corp Polisulfato de pentosan y metodo para producir polisulfato de pentosan.
WO2019124363A1 (fr) 2017-12-20 2019-06-27 王子ホールディングス株式会社 Pentosane polysulfate et médicament contenant du pentosane polysulfate
WO2019165498A1 (fr) 2018-02-28 2019-09-06 Paradigm Biopharmaceuticals Ltd Traitement de la douleur articulaire post-opératoire avec des polysaccharides polysulfatés
CN109125341A (zh) * 2018-06-11 2019-01-04 广西壮族自治区中国科学院广西植物研究所 木聚糖在制备预防或治疗骨质疏松的药物或食品中的应用
JP2022512662A (ja) 2018-10-10 2022-02-07 パラダイム バイオファーマシューティカルズ リミテッド ポリ硫酸化多糖を用いた疼痛の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE364636B (fr) * 1968-01-16 1974-03-04 S Ericsson
ATE129254T1 (de) * 1987-03-19 1995-11-15 Arthropharm Pty Ltd Antientzündungsmittel und zusammensetzungen.
FR2691066B1 (fr) * 1992-05-15 1995-06-09 Sanofi Elf Utilisation de glycosaminoglycanes exogenes, de leurs analogues ainsi que de leurs fragments, fractions et derives, pour la preparation de medicaments destines au traitement de thrombopenies.
NZ511506A (en) * 1998-10-28 2004-02-27 Sankyo Co Remedies for bone metabolic errors comprising OCIF

Also Published As

Publication number Publication date
EP1335733A4 (fr) 2006-03-22
EP1335733B1 (fr) 2007-03-28
CA2426929A1 (fr) 2002-05-30
ATE357923T1 (de) 2007-04-15
CN1476328A (zh) 2004-02-18
EP1335733A1 (fr) 2003-08-20
WO2002041901A1 (fr) 2002-05-30
DE60127575D1 (de) 2007-05-10
US6593310B1 (en) 2003-07-15
DE60127575T2 (de) 2007-12-06
JP2004513185A (ja) 2004-04-30

Similar Documents

Publication Publication Date Title
EP1335733B1 (fr) Traitement de l'osteoporose
US7498311B2 (en) Treatment of migraine
EP1286667B1 (fr) Composition pour le traitement et/ou la prevention de l'osteoporose et/ou de maladies inflammatoires des articulations
MX2010012656A (es) Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo.
MXPA00009159A (es) Formulaciones de dextrano y metodo para el tratamiento de desordenes inflamatorios de articulaciones.
EP1906975A2 (fr) Methode destinee a traiter la drepanocytose et les sequelles de la drepanocytose
EA000347B1 (ru) Способ уменьшения риска невертебральных переломов костей
JP2003089647A (ja) 関節性疾患治療剤
EP2292243A1 (fr) Mélange d'acide hyaluronique pour traiter et empêcher les maladies intestinales inflammatoires
US5508392A (en) Use of vitamin D glycosides, vitamin D orthoester glycosides, vitamin D analog glycosides and vitamin D analog orthoester glycosides for the treatment of osteoporosis
US4820693A (en) Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
ES2731582T3 (es) Derivados de glicosaminoglicanos N-desulfatados y su uso como fármacos
KR100958691B1 (ko) 임부의 효과적인 분만을 유도하기 위한 황산화글리코스아미노글리칸의 용도
CA2226140C (fr) Composes pour traiter ou prevenir l'osteosporose et les symptomes associes avec la menopause
JPH0873376A (ja) 骨粗鬆症治療薬
Dixit et al. Effect of insulin on the incorporation of citrate and calcium into the bones of alloxan-diabetic rats
JP2002029974A (ja) 脱髄性疾患処置剤
KR970703759A (ko) 바이러스 감염 및 임의의 염증의 예방 및/또는 치료용 약학 조성물 및 이의 치료 방법(a pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof)
US6436911B1 (en) IL-12 production inhibitor
US20090149423A1 (en) Use for a very low molecular weight heparins
Hansen et al. [99mTc] Diphosphonate uptake and hemodynamics in experimental arthritis: Effect of naproxen in the canine carrageenan injection model
JP4456698B2 (ja) エンドトキシンショック抑制剤
AU2003205664A1 (en) Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
WO2003063881A1 (fr) Idraparinux (sanorg 34006) concu pour traiter et prevenir de maniere secondaire des evenements thromboemboliques veineux chez des patients presentant une thrombose veineuse profonde
HUT64935A (en) Method for producing sulphated poly-beta-2,6-fructofuranosanes of low molecular mass and one for preparing medical preparatives containing said compounds as active substance

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted